MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma

• Status: Recruiting
• Trial end date: 2026-08-17
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the Recommended Phase 2 Dose and clinical benefit of elranatamab in combination with other anti-cancer therapies in participants with multiple myeloma.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer

Criteria

Inclusion Criteria:

• Relapsed/refractory multiple myeloma with at least 3 prior lines of therapy

• Refractory to at least one IMiD, one proteasome inhibitor, and one anti-CD38 antibody

• Measurable disease defined by at least one of the following:

1. Serum M-protein >/= 0.5 g/dL by SPEP

2. Urinary M-protein excretion >/= 200 mg/24 hours by UPEP

3. Serum immunoglobulin FLC >/= 10 mg/dL (>/= 100 mg/L) AND abnormal serum immunoglobulin kappa to lambda FLC ratio

• ECOG performance status 0 -1

• Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade Exclusion Criteria:

• Active plasma cell leukemia

• Amyloidosis

• Stem cell transplant with 12 weeks prior to enrollment, or active GVHD

• POEMS syndrome

• Any active uncontrolled bacterial, fungal, or viral infection

• Impaired cardiovascular function or clinically significant cardiovascular diseases within 6 months prior to enrollment

• Previous treatment with an anti-BCMA bispecific antibody

• Previous administration with an investigational drug within 30 days or 5 half-lives preceding the first dose of study treatment (whichever is longer)